MP 0250

Drug Profile

MP 0250

Alternative Names: DARPins® - Molecular Partners; Designed repeat proteins research programme - Molecular Partners; DPR research programme - Molecular Partners; MP0250

Latest Information Update: 14 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Molecular Partners AG
  • Class Antineoplastics; Proteins; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Hepatocyte growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma; Solid tumours

Most Recent Events

  • 23 May 2017 Phase-I/II clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in Germany (IV) (NCT03136653)
  • 27 Oct 2016 Interim adverse events data from a phase I/II trial in Solid tumours presented at the European Cancer Congress (Joint meeting of the 18th European CanCer Organisation (ECCO) and the 40th European Society for Medical Oncology Congress (ESMO) - ECC - 2016)
  • 09 Oct 2016 Molecular Partners AG plans a phase II trial for Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top